josef stehlik, md, mph associate professor of medicine medical director, heart transplant program...
TRANSCRIPT
![Page 1: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/1.jpg)
Josef Stehlik, MD, MPHAssociate Professor of Medicine
Medical Director, Heart Transplant ProgramUniversity of Utah School of MedicineDirector, ISHLT Transplant Registry
No financial relationships to disclose.
Are DT / BTT designations still relevant?
![Page 2: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/2.jpg)
Are DT / BTT designations still relevant?
• The answer may depend on who is asking
1. Payer (health insurance)
2. Provider (advanced heart failure team)
3. Patient
![Page 3: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/3.jpg)
1. Payer perspective
• VAD indication important for eligibility determination and for budgeting
![Page 4: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/4.jpg)
Payer view
• (Increasing number of) private insurers - declare indication as BTT vs DT - BTT patients must be listed for transplant before VAD implant
• (Some) state Medicaid programs - no BTT durable MCS
• VHA - federal insurer - ‘… heart failure treatment utilizing a VAD or total artificial heart …’
![Page 5: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/5.jpg)
2. Provider perspective (us)
![Page 6: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/6.jpg)
![Page 7: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/7.jpg)
![Page 8: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/8.jpg)
![Page 9: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/9.jpg)
2008-2011
Wever-Pinzon O, Stehlik J. Circulation 2013 Jan 29;127(4)
Waiting list mortality
![Page 10: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/10.jpg)
Transplant rate
Colvin-Adams M. AJT 2014
UNOS Status
Transplanted in status
Median waiting time
1A
1B
2
64%
31%
5%
78 days
224 days
618 days
Stehlik J, Stevenson LW, Mehra MR.JHLT Oct 2014
![Page 11: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/11.jpg)
• Is this a scientific / clinical care proposition or rather expression of desperation?
Are DT / BTT designations still relevant?
![Page 12: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/12.jpg)
Proposed revision of US heart allocation
Meyer DM, AJT 2014
![Page 13: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/13.jpg)
3. Patient perspective
• 22-year old patient
![Page 14: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/14.jpg)
Expected survival – 22 year old male
99.4% 99.0%
National Vital Statistics Reports. 58 (21), 2010
![Page 15: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/15.jpg)
Clinical scenario
• 22-year-old• Non-ischemic CM• NYHA IV / Stage D, now inotrope dependent
![Page 16: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/16.jpg)
Expected survival
![Page 17: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/17.jpg)
Expected survival – heart transplant
![Page 18: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/18.jpg)
Expected survival – DT VAD
Data courtesy of Kirklin JK, Naftel DC
![Page 19: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/19.jpg)
Expected survival - BTT VAD
Data courtesy of Kirklin JK, Naftel DC
![Page 20: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/20.jpg)
Expected survival - BTT VAD
Data courtesy of Kirklin JK, Naftel DC
![Page 21: Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT](https://reader030.vdocuments.net/reader030/viewer/2022033104/56649e5d5503460f94b565de/html5/thumbnails/21.jpg)
Are DT / BTT designations still relevant?
• Payer - relevant for budgeting (eligibility determination, reimbursement)
• Provider - prefer the flexibility of adjusting strategy based on circumstances
• Patient - does not care about our terminology - wants to know the options and likely outcomes to make informed decisions